News Search Results
Mar 27, 2025, 12:00 ET ICON plc (ICLR) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
offerings were insufficient to shield the Company from the adverse effects of a significant market downturn; (3) that the RFPs ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: Glancy Prongay & Murray LLP
Mar 27, 2025, 10:45 ET Single-cell Analysis Market Surges to USD 5.4 Billion by 2033, Propelled by 9.5% CAGR - Verified Market Reports®
Development, Cancer Research), By End-User (Pharmaceutical Companies, Biotechnology Firms), By Technology (Label-Free Technology, Fluorescent Technology), By End-User (Academia and Research Institutes, Pharmaceutical and Biotechnology Companies), By Geographic Scope And Forecast
More news about: Verified Market Reports
Mar 27, 2025, 10:01 ET Precision Fermentation Market is expected to generate a revenue of USD 34.2 Billion by 2031, Globally, at 40.1% CAGR: Verified Market Research®
Precision fermentation is revolutionizing the food and biotechnology industries by enabling the production of high-value ingredients, alternative proteins, and bio-based compounds. Leveraging microbial hosts for targeted
More news about: Verified Market Research
Mar 27, 2025, 09:25 ET Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions
website: www.scinai.com About Pincell srl PinCell is a biotechnology company targeting a novel pathological pathway to develop first-in-class anti-inflammatory therapies for the treatment of rare, severe and highly
More news about: Scinai Immunotherapeutics Ltd.
Mar 27, 2025, 09:00 ET LillyDirect platform expands to facilitate access to Alzheimer's disease care
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Mar 27, 2025, 08:05 ET Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation
a registered trademark of Rigel Pharmaceuticals, Inc. About RigelRigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders
More news about: Rigel Pharmaceuticals, Inc.
Mar 27, 2025, 08:00 ET BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints
Dermata Therapeutics, Inc. (Nasdaq: DRMA, DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, today announced positive topline results from the Company's
More news about: Dermata Therapeutics, Inc.
Mar 27, 2025, 07:33 ET GlycoNex to Present Preclinical Data on GNX1021 at AACR 2025
GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of glycan-directed cancer immunotherapies, today announced that preclinical data on GNX1021 will be presented
More news about: GlycoNex, Inc.
Mar 27, 2025, 07:00 ET CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates
announced the appointment of Alan Glicklich, M.D., to the Company's Board of Directors. Dr. Glicklich has more than 20 years of experience in the biotechnology industry and currently serves as Chief Medical Officer of Nuvig Therapeutics. Previously, he was Chief Medical Officer of Chinook Therapeutics.Other
More news about: CalciMedica, Inc.
Mar 27, 2025, 06:15 ET Epson Signs Bertelkamp Automation as an AutomateFirst Gold Partner
of experience, Epson Robots delivers robots for precision assembly and material handling applications in the aerospace, appliance, automotive, biotechnology, consumer product, electronics, food processing, medical device, pharmaceutical, plastics, semiconductor, and telecommunication industries. For
More news about: Epson America, Inc.
Mar 27, 2025, 05:45 ET The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 20, 2025 in Sana Biotechnology, Inc. Lawsuit - SANA
March 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA).
More news about: The Gross Law Firm
Mar 27, 2025, 05:45 ET The Gross Law Firm Reminds ICON Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 11, 2025 - ICLR
insufficient to shield the Company from the adverse effects of a significant market downturn; (c) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: The Gross Law Firm
Mar 27, 2025, 04:00 ET ARTHEx Biotech to Participate in the 24th Annual Needham Virtual Healthcare Conference
Spain, March 27, 2025 /PRNewswire/ -- ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of gene expression, announced today its participation in the 24th
More news about: ARTHEx Biotech
Mar 27, 2025, 03:12 ET Lupin Digital Health Introduces Comprehensive Post-Procedure Home-Based Care Guide in Collaboration with the American College of Cardiology
products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position
More news about: Lupin Limited
Mar 27, 2025, 01:29 ET Celltrion's STEQEYMA® (ustekinumab-stba), now added to the Costco Member Prescription Program
ZYMFENTRA® (infliximab-dyyb). Celltrion USA will continue to leverage Celltrion's unique heritage in biotechnology, supply chain excellence and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients. For more information,
More news about: Celltrion
Mar 26, 2025, 16:05 ET Congruence Therapeutics Announces Participation in the 24th Annual Needham Virtual Healthcare Conference
March 26, 2025 /PRNewswire/ -- Congruence Therapeutics, a computationally-driven biotechnology company building a unique pipeline of correctors for diseases of protein misfolding, including MC4R-deficient genetic obesity, GBA-driven Parkinson's
More news about: Congruence Therapeutics
Mar 26, 2025, 16:00 ET SANA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ: SANA) and certain of its officers.
More news about: Bronstein, Gewirtz & Grossman, LLC
Mar 26, 2025, 14:40 ET ICON Public Limited Company Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds ICON Public Limited Company Investors of Deadline in Securities Fraud Class Action Lawsuit
insufficient to shield the company from the adverse effects of a significant market downturn; (3) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: Kessler Topaz Meltzer & Check, LLP
Mar 26, 2025, 12:00 ET AnHorn Medicines Announces First Subject Dosed in AH-001 Phase I Clinical Trial in the United States
market. The company will continue to provide updates as the trial progresses. About AnHorn MedicinesAnHorn is a clinical-stage biotechnology company dedicated to revolutionizing drug discovery through AI-powered innovation. By integrating artificial intelligence with cutting-edge molecular
More news about: AnHorn Medicines
Mar 26, 2025, 10:01 ET CAR T-Cell Therapy Market Size To Reach 27.5 Billion by 2033 Owing to Rising Awareness and Favourable Reimbursement Policies Says Astute Analytica
biomanufacturing innovations. With increasing clinical success and expanding treatment indications, the market presents significant opportunities for biotechnology companies, healthcare providers, and investors to revolutionize cancer care. Industry experts predict a surge in the development of next-generation
More news about: Astute Analytica
Mar 26, 2025, 10:00 ET JULABO USA EXPANDS NATURAL REFRIGERANT OFFERINGS WITH NEW PRODUCTS
chillers, water baths, immersion coolers, and complementary accessories. JULABO customers span multiple industries including Aerospace, Automotive, Biotechnology, Cannabis, Chemical Manufacturing, Academia, Food & Beverage, Pharmaceutical, Semiconductor and more. Contact Tricia
More news about: Julabo USA
Mar 26, 2025, 08:15 ET BrainStorm Cell Therapeutics Granted Compliance Extension from Nasdaq
March 26, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading biotechnology company committed to the development and commercialization of best-in-class autologous cellular therapies for the treatment of neurodegenerative
More news about: BrainStorm Cell Therapeutics Inc.
Mar 26, 2025, 08:00 ET Sapience Therapeutics to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025
March 26, 2025 /PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, today
More news about: Sapience Therapeutics, Inc.
Mar 26, 2025, 07:16 ET Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma
March 26, 2025 /PRNewswire/ -- Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneering biotechnology company focused on developing innovative immunotherapies, today announced final data from the successful conclusion of its open-label Phase 2a clinical
More news about: OSR Holdings Inc.
Mar 26, 2025, 07:05 ET Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Mass., March 26, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended
More news about: Leap Therapeutics, Inc.